Zacks Research Issues Optimistic Outlook for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research report issued to clients and investors on Thursday, October 24th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will earn $0.81 per share for the quarter, up from their prior forecast of $0.80. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.31 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.98 EPS, FY2025 earnings at $3.68 EPS, Q2 2026 earnings at $1.11 EPS and FY2026 earnings at $4.03 EPS.

MMSI has been the topic of a number of other research reports. StockNews.com upgraded Merit Medical Systems from a “hold” rating to a “buy” rating in a report on Saturday. Bank of America increased their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a report on Monday, September 16th. Barrington Research restated an “outperform” rating and set a $114.00 target price on shares of Merit Medical Systems in a report on Friday, October 18th. Needham & Company LLC reissued a “buy” rating and set a $105.00 price target on shares of Merit Medical Systems in a research report on Monday, September 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.82.

Merit Medical Systems Trading Up 0.1 %

Shares of MMSI opened at $96.00 on Monday. Merit Medical Systems has a 1-year low of $63.13 and a 1-year high of $101.60. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of 48.00, a PEG ratio of 2.41 and a beta of 0.87. The firm’s 50-day moving average price is $96.11 and its 200-day moving average price is $87.15. The company has a current ratio of 6.24, a quick ratio of 4.64 and a debt-to-equity ratio of 0.62.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.04. The company had revenue of $338.00 million during the quarter, compared to the consensus estimate of $334.94 million. Merit Medical Systems had a return on equity of 15.29% and a net margin of 9.02%.

Hedge Funds Weigh In On Merit Medical Systems

Hedge funds and other institutional investors have recently modified their holdings of the company. Opal Wealth Advisors LLC bought a new stake in Merit Medical Systems during the second quarter valued at approximately $29,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Merit Medical Systems during the first quarter worth about $44,000. Headlands Technologies LLC bought a new stake in shares of Merit Medical Systems during the first quarter valued at approximately $50,000. USA Financial Formulas bought a new position in shares of Merit Medical Systems during the 3rd quarter valued at about $59,000. Finally, EntryPoint Capital LLC grew its holdings in Merit Medical Systems by 2,666.7% during the 1st quarter. EntryPoint Capital LLC now owns 913 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 880 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.